OTX015 PROTACs: Emerging Novel Therapeutic Agents in Cancer Treatment

Author:

Kaur Rajwinder,Singh Pargat,Kaur Amritpal,Chaudhary Gaurav,Choudhary Diksha,Kaur Paranjeet,Kumar Sahu Sanjeev

Abstract

Cancer is a wide-spreading disease. Its count goes on increasing and became the second leading cause of death in respect of diseases. New cancer-targeting molecules are explored. In this study, we tried to collect information about one such molecule, OTX015. Articles were searched across reputed search engines and publishers such as Cochrane, EMBASE, The Lancet, PubMed, GoogleScholar, ScienceDirect, Wiley Online, Springer and Bentham Science by using different keywords: “OTX015”, “Cancer”, “Small molecule PROTACs”, “BRD/BET” and “BET inhibitors”. The quality papers were retrieved, studied, categorized into different sections, analyzed, and used for article writing.OTX015 is a novel molecule in clinical trials. It showed some promising results in various cancers as well as other diseases like latent-HIV with the least side-effects.This article will give an insight into Small Molecules as PROTACs, their advantages and disadvantages, OTX015 and its PROTAC ARV- 825. It is advised that more research/studies are required to be carried out to know more about OTX015 and other PROTACs, their advancements, receptors, and mechanism/ mode of action to know their abilities to work against proteins involving diseases.

Publisher

EDP Sciences

Reference57 articles.

1. Identification of the functional alteration signatures across different cancer types with support vector machine and feature analysis

2. Recent advances in cancer chemoprevention with phytochemicals

3. Elflein J. Cancer - Statistics & Facts. 2020; https://www.statista.com/topics/1192/cancer-in-the-us/ (accessed on 2020 Aug 27).

4. Lung cancer type classification using differentiator genes

5. Elflein J. Cancer death rate worldwide by type of cancer in 2018. 2019; https://www.statista.com/statistics/1031260/cancer-death-rate-worldwide-by-type/ (accessed on 2020 Aug 27).

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3